Bromperidol is a multifaceted bioactive compound with wide-ranging pharmacological effects and tissue distribution profiles. After intravenous administration in rats at a dose of 0.2 mg/kg, it exhibits significant distribution across multiple organs, including the brain, liver, kidney, lungs, and spleen, persisting up to 8 hours post-administration, with the highest initial concentration observed in the lungs. The compound shows prominent inhibitory activity against Acid Sphingomyelinase (ASM) in rat PC12 cells and human tyrosyl-DNA phosphodiesterase 1, alongside several cytochrome P450 enzymes, TGF-b, and AmpC Beta-Lactamase, reflecting its diverse bioactivity spectrum.
Moreover, Bromperidol displays antiviral properties, inhibiting SARS-CoV-2-induced cytotoxicity in various cell lines and showing partial inhibition of the SARS-CoV-2 3CL-Pro protease. It also demonstrates antifungal activity with synergistic effects when combined with specific antifungal drugs. While exhibiting moderate liver toxicity, including hepatotoxicity, it lacks evidence of causing other types of liver damage such as steatosis or tumor formation.
In terms of antibacterial properties, the compound inhibits Mycobacterium tuberculosis Eis enzyme and potentiates kanamycin-induced activity against Mycobacterium tuberculosis, although it shows limited activity against other mycobacterial strains. Additionally, it binds multiple human receptors and transporters, contributing to its wide-ranging pharmacological effects.
In conclusion, Bromperidol represents a versatile bioactive agent with significant potential across multiple therapeutic areas, though its moderate liver toxicity and variable activity across different pathogens necessitate further investigation..
Note: Summary generated by AI. Data source: ChEMBL 